Medical Condition News

RSS

DSS VistA Chemotherapy Manager goes live at San Francisco VA Medical Center

DSS, Inc., a leading provider of software development, integration, project management, implementation and support of VistA, today announced that its customized VistA Chemotherapy Manager (VCM) system is now live and in production at the San Francisco VA Medical Center.

7 Nov 2011

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).

7 Nov 2011

HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting

Baxter International Inc. today announced the presentation of its phase III study data for HyQ, an investigational combination immunoglobulin (IG) product for use in patients with primary immunodeficiencies (PI).

From Baxter International Inc. 7 Nov 2011

Medtronic CoreValve System for direct aortic and subclavian implantation receives CE Mark

Medtronic, Inc. today announced it has received CE Mark for the Medtronic CoreValve System to be delivered using direct aortic access.

From Medtronic 7 Nov 2011

NanoString closes $20M Series D round of equity financing

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it has closed $20 million in a Series D round of equity financing.

From NanoString Technologies 7 Nov 2011

Mediterranean Diet beneficial even without weight loss

The benefits of the Mediterranean Diet go beyond weight loss, even when weight loss isn't achieved. Researchers from St. Vincent's Hospital, Melbourne, studied 12 patients without diabetes who had nonalcoholic fatty liver disease (NAFLD), and the results of their study demonstrated that liver health was improved even without weight loss.

7 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

Gifts established at Case Western Reserve to educate physicians in integrative oncology

Case Western Reserve University School of Medicine is honored to announce gifts to establish the inaugural Parker Hannifin - Helen Moss Cancer Research Foundation Professorship in Integrative Oncology. This professorship will establish the School of Medicine and its affiliate hospitals as national leaders in teaching, research, and patient care in the field of integrative oncology.

7 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

InfraReDx TVC Imaging System to be exhibited at TCT 2011

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System for the true vessel characterization of coronary artery disease will be highlighted during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2011).

7 Nov 2011

DuoCort Pharma granted marketing authorization for adrenal insufficiency drug, Plenadren in Europe

The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.

7 Nov 2011

InfraReDx launches enhanced version of LipiScan IVUS Coronary Imaging System

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced the launch of its TVC Imaging System, an enhanced version of the LipiScan IVUS Coronary Imaging System.

7 Nov 2011

MILV subsidiary acquires formula to restore proper kidney function

Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. announced that it has executed the formal closing documents and acquired the chronic kidney disease formula. This formula was developed to restore proper kidney function.

7 Nov 2011

ISET 2012 to discuss latest advances in chronic cerebrospinal venous insufficiency

Innovators in the field of endovascular therapy will explore the often-contentious topic of chronic cerebrospinal venous insufficiency (CCSVI), which is theorized to be a contributing factor in the development of multiple sclerosis (MS), at the 24th annual International Symposium on Endovascular Therapy.

7 Nov 2011

SweetSpot announces initiative to monitor blood glucose levels in veterans with diabetes

SweetSpot Diabetes Care, Inc. today announced an initiative to remotely monitor blood glucose levels in veterans with diabetes, which will be funded by an award from The U.S. Department of Veteran Affair's industry innovation competition known as VAi2.

7 Nov 2011

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced positive top-line results from REPLACE, a Phase 3 registration study of NPSP558, the company's bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients.

7 Nov 2011

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

Researchers discover key mechanism responsible for degrading ubiquitinated protein aggregates

Researchers at the RIKEN Brain Science Institute (BSI) have discovered a key mechanism responsible for selectively degrading aggregates of ubiquitinated proteins from the cell.

7 Nov 2011

Scientists achieve major step toward goal of producing synthetic Taxol

Taxanes are a family of compounds that includes one of the most important cancer drugs ever discovered, Taxol, among other cancer treatments. But the difficulty producing these complex molecules in the lab has hampered or blocked exploration of the family for further drug leads. Now, a group of Scripps Research Institute scientists has successfully achieved a major step toward the goal of synthetically producing Taxol and other complex taxanes on a quest to harness chemical reactions that could enable research on previously unavailable potential drugs.

7 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

Medical Condition News

DSS VistA Chemotherapy Manager goes live at San Francisco VA Medical Center

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting

Medtronic CoreValve System for direct aortic and subclavian implantation receives CE Mark

NanoString closes $20M Series D round of equity financing

Mediterranean Diet beneficial even without weight loss

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Gifts established at Case Western Reserve to educate physicians in integrative oncology

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

InfraReDx TVC Imaging System to be exhibited at TCT 2011

DuoCort Pharma granted marketing authorization for adrenal insufficiency drug, Plenadren in Europe

InfraReDx launches enhanced version of LipiScan IVUS Coronary Imaging System

MILV subsidiary acquires formula to restore proper kidney function

ISET 2012 to discuss latest advances in chronic cerebrospinal venous insufficiency

SweetSpot announces initiative to monitor blood glucose levels in veterans with diabetes

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

Abbott announces results from HUMIRA Phase 3 study on axSpA

Researchers discover key mechanism responsible for degrading ubiquitinated protein aggregates

Scientists achieve major step toward goal of producing synthetic Taxol

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

This International Women’s Day, Meet the Scientist Changing Women’s Healthcare

Microphysiological systems in drug discovery

Considerations for taking ASO discovery programs into animal models

Latest News